Skip to main content
Caplight Logo









Aplagon

Aplagon

Private
HelsinkiHealthcare & Life Scienceshttps://aplagon.com/

Last Round

Early Funding

Jun 16, 2026

Total Funding Raised

$15.02M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Aplagon is a clinical-stage biopharmaceutical company that develops first-in-class therapeutics for thromboinflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

thrombo-inflammatory diseaseclinical-stage biopharmaantithrombotic therapyvascular injury treatmentchronic limb-threatening ischemiaCLTIarteriovenous fistulaAV fistulablood thinnerheparin mimeticanticoagulant therapyantiplatelet therapyhemodialysis complicationsperipheral arterial diseasefirst-in-class drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aplagon Comparables

Compare Aplagon with similar companies based on industry and business-model similarity.

Aplagon comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Sanofi
69%
Bioxodes
65%
Pfizer
62%

Aplagon Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingJun 16, 2026
Series AFeb 3, 2025
GrantNov 16, 2022
VC RoundMay 28, 2021
SeedDec 7, 2018

Aplagon Investors

Notable investors and investment history

Aplagon investors
InvestorRounds
European Innovation Council FundEarly Funding, Series A
InnovestorEarly Funding, Series A, Seed
Helsinki University FundsSeed
InvesdorVC Round
Fåhraeus Startup and GrowthEarly Funding, Series A
FinnveraSeed
Jenny and Antti Wihuri FoundationEarly Funding, Series A, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Monthly visitors grew 36% MoM, from 461 to 627.

  • Jun 16, 2026

    $6M raised with eic-ec-europa and Fåhraeus Startup and Growth leading.

Recent news

Latest coverage and updates

  • is_developingJun 30, 2026

    Aplagon Oy is developing APAC on Jun 30th '26.

  • hiresJun 29, 2026

    Aplagon Oy hired Carl Lindgren as Chair of Board of Directors on Jun 29th '26.

Aplagon Filings

Explore SEC and related filing metadata, where available.

Aplagon filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Aplagon's valuation, stock price, and market status.

Is Aplagon a public or private company?

Aplagon is a private company.

What is the current stock price of Aplagon?

Aplagon is a private company with no public stock price. No recent secondary market data is available.

How much is Aplagon worth (valuation)?

Valuation information for Aplagon is not publicly available.

Can I buy Aplagon stock?

Aplagon shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Aplagon's last funding round?

Aplagon's most recent funding round was Early Funding on June 16, 2026.

Who are the main investors in Aplagon?

Key investors in Aplagon include European Innovation Council, Fåhraeus Startup and Growth.

Will Aplagon IPO soon?

No public IPO plans have been announced for Aplagon.

How can I track Aplagon secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Aplagon's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersHelsinki
Employee Range8
Year Founded2009
Last FundingJun 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?